Bladder cancer patients may get new hope from virus treatment

NCT ID NCT07356791

Not yet recruiting Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a virus-based drug given directly into the bladder for people with high-risk non-muscle invasive bladder cancer. The virus is designed to attack cancer cells and trigger the immune system. About 18 participants will receive increasing doses to find the safest and most effective level, with the goal of clearing tumors and preventing their return.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human adenovirus type 5 injection
What this could lead to: If it works, this could offer a new treatment option for high-risk bladder cancer patients who have limited alternatives, potentially clearing tumors and delaying recurrence.
What could go wrong: This is a small, early-phase trial with only 18 participants, so results may not apply to everyone. The virus-based therapy can cause side effects like bladder irritation, infection, or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm superficial urinary bladder carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.